Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,300.0 million
Deal Type : Collaboration
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
Details : The collaboration focuses on the discovery of RNA therapeutics for sensorineural hearing loss. Rznomics will conduct early research, while Lilly will assume further development and commercialization.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 15, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,300.0 million
Deal Type : Collaboration
Lead Product(s) : RZ-001,Atezolizumab,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rznomics Inc. Liver Cancer Drug Candidate Secures Fast Track Designation
Details : RZ-001 is an anti-HCC activity by suppressing hTERT expression selectively in cancer cells. It is being in combination with valganciclovir for the treatment of hepatocellular carcinoma.
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : RZ-001,Atezolizumab,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rznomics Secures Expanded Access for Glioblastoma Patients with Novel Therapy
Details : RZ-001 is an anti-HCC activity by suppressing hTERT expression selectively in cancer cells. It is being in combination With valganciclovir for the treatment in 18 and older with Glioblastoma.
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rznomics Secures Orphan Drug Designation for RZ-001 in Hepatocellular Carcinoma
Details : RZ-001, which selectively suppresses hTERT expression in cancer cells, is under Phase 1/2 clinical trials combined with valganciclovir for hepatocellular carcinoma.
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 02, 2024
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001
Details : RZ-001, the RNA replacement enzyme-based cancer gene therapy for the treatment of GBM, targets and cleaves hTERT mRNA and replaces the mRNA with the therapeutic gene RNA.
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 11, 2023
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Partnership
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
Details : Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients. RZ-001 is the first ribozyme-based RNA reprogramming approach approved by the US FDA...
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 18, 2023
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RZ-001 engenders effective anti-HCC activity by suppressing hTERT expression selectively in cancer cells, which over-express hTERT, and simultaneously inducing a cytotoxic effect by trans ligating an HSVtk-encoding sequence into the reprogrammed hTERT mR...
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 25, 2022
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable